---
schema_version: "secwatch.filing_event.v1"
accession: "0001576280-23-000019"
form_type: "8-K"
ticker: "GH"
cik: "0001576280"
company_name: "Guardant Health, Inc."
filed_at: "2023-02-23T23:59:59+00:00"
generated_at: "2026-06-19T02:40:19.040361+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Guardant Health Q4 revenue $126.9M (+17% YoY); net loss widens to $139.9M; guides FY23 rev $525-540M

## Summary
- Q4 revenue $126.9M (+17% YoY); full-year revenue $449.5M (+20% YoY).
- Q4 clinical test volume 36,000 (+41% YoY); biopharma 8,200 (+24% YoY).
- Q4 net loss $139.9M ($1.36/share) vs $90.9M ($0.89) prior year; non-GAAP net loss $119.6M.
- FY23 revenue guidance $525-540M (17-20% growth); expects free cash outflow ~$350M.
- ECLIPSE study for Shield CRC screening showed 83% sensitivity, 90% specificity; FDA approved Guardant360 CDx for breast cancer.

## SEC filing metadata
- accession: 0001576280-23-000019
- form_type: 8-K
- ticker: GH
- cik: 0001576280
- company_name: Guardant Health, Inc.
- filed_at: 2023-02-23T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1576280/000157628023000019/0001576280-23-000019-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1576280/000157628023000019/gh-20230223.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001576280-23-000019
- JSON: https://secwatch.observer/filing/0001576280-23-000019.json
- Plain text: https://secwatch.observer/filing/0001576280-23-000019.txt

## Key facts
- Earnings Releases
  Guardant Health, Inc. reported the year ended December 31, 2022 results: revenue $449.5 million, net income $654.6 million, EPS $6.41 per share.
  - Period: the year ended December 31, 2022
  - Revenue: $449.5 million
  - Net income: $654.6 million
  - EPS: $6.41 per share
  - Result: reported results
  source text: customers in the fourth quarter of 2022, representing an increase of 41% and 24%, respectively, over the fourth quarter of 2021. Full Year 2022 Financial Highlights • Revenue of $449.5 million for the full year 2022, an increase of 20% over the full year 2021. • Reported 124,800 tests to clinical customers and 26,000 tests to biopharmaceutical customers in the full
  evidence_url: https://www.sec.gov/Archives/edgar/data/1576280/000157628023000019/0001576280-23-000019-index.htm
- Earnings Releases
  Guardant Health, Inc. reported the three months ended December 31, 2022 results: revenue $126.9 million, net income $139.9 million, EPS $1.36 per share.
  - Period: the three months ended December 31, 2022
  - Revenue: $126.9 million
  - Net income: $139.9 million
  - EPS: $1.36 per share
  - Result: reported results
  source text: data sets and advanced analytics, today reported financial results for the quarter and full year ended December 31, 2022. Fourth Quarter 2022 Financial Highlights • Revenue of $126.9 million for the fourth quarter of 2022, an increase of 17% over the fourth quarter of 2021. • Reported 36,000 tests to clinical customers and 8,200 tests to biopharmaceutical customers
  evidence_url: https://www.sec.gov/Archives/edgar/data/1576280/000157628023000019/0001576280-23-000019-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.